Vor Biopharma Aktie

Vor Biopharma für 0 Euro bei ZERO ordern (zzgl. Spreads)

WKN DE: A2QNC7 / ISIN: US9290331084

<
Kurse + Charts + Realtime
Kurs + Chart
Times + Sales
Börsenplätze
>
<
News + Analysen
News + Adhoc
Analysen
Kursziele
>
<
Unternehmen
Termine
Profil
>
<
zugeh. Wertpapiere
Zertifikate
Optionsscheine
Knock-Outs
>
26.06.2025 13:09:37

Why Vor Bio Is Rising In Pre-market?

(RTTNews) - Vor Bio (VOR) and RemeGen Co. announced entry into a license agreement granting Vor Bio global rights excluding China, Hong Kong, Macau and Taiwan to develop and commercialize telitacicept, a dual-target fusion protein approved in China for generalized myasthenia gravis, systemic lupus erythematosus, and rheumatoid arthritis. Vor Bio will pay RemeGen an initial payment of $125 million consisting of an upfront payment of $45 million as well as $80 million of warrants to purchase common stock with an exercise price of $0.0001 per share. The agreement provides for potential regulatory and commercial milestones exceeding $4 billion, in addition to tiered royalties.

Vor Bio also announced that its Board has appointed Jean-Paul Kress, as Chief Executive Officer and Chairman of the Board. This follows Robert Ang's resignation from the positions of CEO and director. Ang will continue with Vor Bio as a strategic advisor to assist in the transition through October 2025. Kress most recently served as Chief Executive Officer of MorphoSys.

Shares of Vor Bio are up 120% in pre-market trade on Thursday.

For More Such Health News, visit rttnews.com.

Nachrichten zu Vor Biopharma Inc Registered Shsmehr Nachrichten

Keine Nachrichten verfügbar.

Analysen zu Vor Biopharma Inc Registered Shsmehr Analysen

Eintrag hinzufügen
Hinweis: Sie möchten dieses Wertpapier günstig handeln? Sparen Sie sich unnötige Gebühren! Bei finanzen.net Brokerage handeln Sie Ihre Wertpapiere für nur 5 Euro Orderprovision* pro Trade? Hier informieren!
Es ist ein Fehler aufgetreten!

Aktien in diesem Artikel